Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureJingrui Yan, Tianxing Zhou, Shangheng Shi, Guohua Mao, Jingbo Xu, Huizhi Sun, Xiuchao Wang, Chongbiao Huang, Deqing Hu, Shengyu Yang, Yukuan Feng, Yongjie Xie, Jihui Hao
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals
10.1016/j.gene.2011.04.007 · 2011
Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
10.1158/1078-0432.ccr-08-1547 · 2008
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
10.1016/s0140-6736(23)00620-7 · 2023
Claudin-18 Is an Early-Stage Marker of Pancreatic Carcinogenesis
10.1369/0022155411420569 · 2011
New Markers of Pancreatic Cancer Identified Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8
10.1097/pas.0b013e31815701f3 · 2008
Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies
2020
Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours
2023
Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma
10.1016/j.prp.2022.154068 · 2022
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
CLDN18.2-targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
10.1038/s41591-025-03783-8 · 2025
Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
10.1016/s1470-2045(24)00636-3 · 2025
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
10.1038/s41591-022-01800-8 · 2022
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
10.1038/s41591-025-03781-w · 2025
Connecting the mechanisms of tumor sex differences with cancer therapy
10.1007/s11010-023-04723-1 · 2024
Sex and gender differences in cancer pathogenesis and pharmacology
10.1007/s12094-025-03894-1 · 2025
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
2019
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications
10.1038/s41568-024-00680-z · 2024
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
10.1016/s1470-2045(18)30261-4 · 2018
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
10.1056/nejmoa2035807 · 2021
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial
10.1016/j.eclinm.2024.103004 · 2025
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
10.1016/s1470-2045(14)70330-4 · 2014
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial
10.1016/j.ejca.2025.116133 · 2026
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
10.1016/j.esmoop.2023.101568 · 2023
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
10.1038/nm.3954 · 2015
Sex hormones, the anticancer immune response, and therapeutic opportunities
10.1016/j.ccell.2025.02.013 · 2025
Estrogen Receptor Signaling in the Immune System
10.1210/endrev/bnac017 · 2023
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
10.1038/s43018-025-00969-4 · 2025
Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment
10.1038/s41568-025-00869-w · 2025
Disease-specific suppressive granulocytes participate in glioma progression
10.1016/j.celrep.2024.115014 · 2024
How Do ROS Induce NETosis? Oxidative DNA Damage, DNA Repair, and Chromatin Decondensation
10.3390/biom14101307 · 2024
Novel cell death program leads to neutrophil extracellular traps
10.1083/jcb.200606027 · 2007
Neutrophils Create an ImpeNETrable Shield between Tumor and Cytotoxic Immune Cells
10.1016/j.immuni.2020.04.009 · 2020
The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer
10.1016/j.immuni.2023.11.002 · 2023
Neutrophils drive vascular occlusion, tumour necrosis and metastasis
10.1038/s41586-025-09278-3 · 2025
Neutrophil extracellular traps - the dark side of neutrophils
10.1172/jci84538 · 2016
p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression
10.1016/j.molcel.2022.12.023 · 2023
Ubiquitination-directed cytosolic DNA degradation governs cGAS-STING-mediated immune response to DNA damage
10.1016/j.ccell.2025.12.013 · 2026
The pleiotropic roles of cGAS–STING signaling in the tumor microenvironment
10.1093/jmcb/mjac019 · 2022
Estrogen promotes tumor metastasis via estrogen receptor beta-mediated regulation of matrix-metalloproteinase-2 in non-small cell lung cancer
10.18632/oncotarget.16992 · 2017
Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage
10.1016/j.molcel.2018.07.034 · 2018
Effector memory T cells induce innate inflammation by triggering DNA damage and a non-canonical STING pathway in dendritic cells
10.1016/j.celrep.2023.113180 · 2023
Mitochondrial DNA released by senescent tumor cells enhances PMN-MDSC-driven immunosuppression through the cGAS-STING pathway
10.1016/j.immuni.2025.03.005 · doi-reference
Relationship between the cGAS−STING and NF-κB pathways-role in neurotoxicity
10.1016/j.biopha.2024.116698 · doi-reference
Regulation of cGAS–STING signalling and its diversity of cellular outcomes
10.1038/s41577-024-01112-7 · doi-reference
Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon
10.1016/j.immuni.2026.05.014 · doi-reference
Senescent-like neutrophils shape angiogenic immunosuppressive niches in colorectal cancer liver metastasis
10.1158/2159-8290.cd-25-0820 · doi-reference
Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps
10.1016/j.ccell.2025.06.007 · doi-reference
NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps
10.1016/j.ccell.2023.02.001 · doi-reference
Neutrophil extracellular traps kill bacteria
10.1126/science.1092385 · doi-reference
Outcome differences by sex in oncology clinical trials
10.1038/s41467-024-46945-x · doi-reference
Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer
10.1136/gutjnl-2023-330480 · doi-reference
Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2008)
10.1111/dote.12147 · doi-reference
Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery: A Randomized Clinical Trial
10.1001/jamanetworkopen.2026.0390 · doi-reference
Inhibition of neutrophil elastase prevents neutrophil extracellular trap formation and rescues mice from endotoxic shock
10.1016/j.biomaterials.2020.119836 · doi-reference
Sivelestat sodium protects against renal ischemia/reperfusion injury by reduction of NETs formation
10.1016/j.abb.2025.110318 · doi-reference
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
10.1016/j.immuni.2020.03.001 · doi-reference
G Protein-Coupled Estrogen Receptor GPER: Molecular Pharmacology and Therapeutic Applications
10.1146/annurev-pharmtox-031122-121944 · doi-reference
Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance
10.1038/onc.2016.370 · doi-reference
Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy
10.1016/j.ccell.2025.02.014 · doi-reference
The cGAS–STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy
10.1016/j.apsb.2021.05.011 · doi-reference